Terminated × Carcinoma, Transitional Cell × Gastrointestinal × Clear all JIVAN
Phase 1 Terminated
21 enrolled
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Phase 1/2 Terminated
73 enrolled
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
Phase 1 Terminated
105 enrolled
A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
Phase 1 Terminated
9 enrolled
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Phase 1 Terminated
88 enrolled
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
Phase 1/2 Terminated
19 enrolled
AM-003
Phase 1 Terminated
5 enrolled
A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations
Phase 1 Terminated
54 enrolled
Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types
Phase 1 Terminated
15 enrolled
PDL1x41BB
Phase 1 Terminated
160 enrolled
A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours
Phase 1/2 Terminated
17 enrolled 20 charts
Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors
Phase 1 Terminated
37 enrolled 32 charts
A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies
Phase 1 Terminated
87 enrolled
TORCH
Phase 1 Terminated
10 enrolled
Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
Terminated
20 enrolled
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Phase 1 Terminated
16 enrolled
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
Phase 1 Terminated
61 enrolled
TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy
Phase 1 Terminated
49 enrolled
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Phase 1/2 Terminated
10 enrolled 14 charts
A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors
Phase 1/2 Terminated
5 enrolled 4 charts
iNSITE2
Phase 2 Terminated
73 enrolled